Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammaplasty | 3 | 2021 | 43 | 1.370 |
Why?
|
| Breast Neoplasms | 9 | 2021 | 1118 | 1.190 |
Why?
|
| Mastectomy, Segmental | 4 | 2021 | 45 | 0.880 |
Why?
|
| Mastectomy | 4 | 2020 | 52 | 0.870 |
Why?
|
| Surgical Flaps | 2 | 2021 | 110 | 0.700 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 11 | 0.530 |
Why?
|
| Thyroidectomy | 3 | 2017 | 31 | 0.480 |
Why?
|
| Recurrent Laryngeal Nerve | 1 | 2013 | 4 | 0.430 |
Why?
|
| Vocal Cord Paralysis | 1 | 2013 | 10 | 0.430 |
Why?
|
| Glottis | 1 | 2013 | 13 | 0.430 |
Why?
|
| Monitoring, Intraoperative | 1 | 2013 | 42 | 0.430 |
Why?
|
| Thyroid Neoplasms | 4 | 2017 | 71 | 0.430 |
Why?
|
| Recovery of Function | 1 | 2013 | 270 | 0.380 |
Why?
|
| Postoperative Complications | 3 | 2019 | 1204 | 0.250 |
Why?
|
| Lymph Nodes | 2 | 2017 | 215 | 0.240 |
Why?
|
| Organ Size | 1 | 2021 | 164 | 0.180 |
Why?
|
| Anatomic Variation | 1 | 2020 | 6 | 0.180 |
Why?
|
| Thoracic Wall | 1 | 2020 | 17 | 0.170 |
Why?
|
| Nipples | 1 | 2019 | 14 | 0.160 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 15 | 0.160 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2019 | 45 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 71 | 0.150 |
Why?
|
| Prognosis | 4 | 2019 | 1597 | 0.150 |
Why?
|
| Neck Dissection | 2 | 2017 | 18 | 0.150 |
Why?
|
| Female | 13 | 2021 | 30720 | 0.150 |
Why?
|
| Middle Aged | 10 | 2021 | 16312 | 0.150 |
Why?
|
| Lymphatic Metastasis | 3 | 2017 | 74 | 0.140 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 2338 | 0.140 |
Why?
|
| Intraoperative Care | 2 | 2016 | 36 | 0.140 |
Why?
|
| Humans | 18 | 2021 | 59374 | 0.130 |
Why?
|
| Breast Implants | 1 | 2016 | 13 | 0.130 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 38 | 0.130 |
Why?
|
| Carcinoma | 1 | 2017 | 116 | 0.130 |
Why?
|
| Gestational Age | 1 | 2016 | 178 | 0.120 |
Why?
|
| Retrospective Studies | 6 | 2019 | 6070 | 0.120 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 674 | 0.120 |
Why?
|
| Adult | 9 | 2019 | 15679 | 0.120 |
Why?
|
| Carcinoma, Papillary | 2 | 2017 | 35 | 0.120 |
Why?
|
| Breast Neoplasms, Male | 1 | 2014 | 14 | 0.120 |
Why?
|
| Thyroid Nodule | 1 | 2014 | 14 | 0.110 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2014 | 56 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 64 | 0.110 |
Why?
|
| Thyroid Gland | 1 | 2014 | 79 | 0.110 |
Why?
|
| Vocal Cords | 1 | 2013 | 6 | 0.110 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2014 | 93 | 0.110 |
Why?
|
| Electromyography | 1 | 2013 | 88 | 0.110 |
Why?
|
| Operative Time | 1 | 2013 | 76 | 0.100 |
Why?
|
| Postoperative Period | 1 | 2013 | 127 | 0.100 |
Why?
|
| Breast Diseases | 1 | 2013 | 39 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 193 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 300 | 0.100 |
Why?
|
| Radiographic Image Enhancement | 1 | 2013 | 97 | 0.100 |
Why?
|
| Laryngoscopy | 1 | 2013 | 61 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 2052 | 0.100 |
Why?
|
| Mammography | 1 | 2013 | 269 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2016 | 2375 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2016 | 3067 | 0.080 |
Why?
|
| Lymph Node Excision | 1 | 2009 | 38 | 0.080 |
Why?
|
| Pregnancy | 1 | 2016 | 2213 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2016 | 5281 | 0.080 |
Why?
|
| Young Adult | 5 | 2017 | 4272 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 152 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2015 | 448 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2008 | 133 | 0.070 |
Why?
|
| Neoplasms, Experimental | 1 | 2008 | 75 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2008 | 190 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 137 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2009 | 331 | 0.070 |
Why?
|
| Supine Position | 2 | 2017 | 31 | 0.070 |
Why?
|
| Neoplasms | 2 | 2014 | 1231 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 354 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 357 | 0.060 |
Why?
|
| Aged | 6 | 2017 | 13406 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 402 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2008 | 941 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 584 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2020 | 41 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2009 | 1368 | 0.040 |
Why?
|
| Prone Position | 1 | 2017 | 27 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2017 | 76 | 0.030 |
Why?
|
| Patient Positioning | 1 | 2016 | 44 | 0.030 |
Why?
|
| Adolescent | 2 | 2017 | 5835 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2015 | 29 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 79 | 0.030 |
Why?
|
| Oleic Acid | 1 | 2014 | 21 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 169 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 59 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 61 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1027 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 248 | 0.030 |
Why?
|
| Probability | 1 | 2014 | 167 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2014 | 191 | 0.030 |
Why?
|
| Disease Management | 1 | 2015 | 220 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 602 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 2013 | 93 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2014 | 526 | 0.020 |
Why?
|
| Lipids | 1 | 2014 | 300 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 5119 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 931 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 914 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 461 | 0.020 |
Why?
|
| Thyroglobulin | 1 | 2009 | 9 | 0.020 |
Why?
|
| Male | 3 | 2017 | 27743 | 0.020 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2009 | 16 | 0.020 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2009 | 15 | 0.020 |
Why?
|
| Polycomb-Group Proteins | 1 | 2009 | 21 | 0.020 |
Why?
|
| Smoke | 1 | 2009 | 23 | 0.020 |
Why?
|
| Sirtuin 1 | 1 | 2009 | 25 | 0.020 |
Why?
|
| Acetylation | 1 | 2009 | 112 | 0.020 |
Why?
|
| Sirtuins | 1 | 2009 | 26 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2009 | 91 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2009 | 258 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 223 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 306 | 0.020 |
Why?
|
| Cysteine | 1 | 2008 | 107 | 0.020 |
Why?
|
| Thalidomide | 1 | 2008 | 32 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 75 | 0.020 |
Why?
|
| Pyrroles | 1 | 2008 | 45 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2008 | 381 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 217 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 2379 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 458 | 0.020 |
Why?
|
| Indoles | 1 | 2008 | 106 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2008 | 255 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 178 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2009 | 271 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2008 | 281 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2008 | 173 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 650 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2008 | 228 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 718 | 0.020 |
Why?
|
| Mice | 2 | 2009 | 10294 | 0.010 |
Why?
|
| Peptides | 1 | 2008 | 549 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 915 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 1910 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 986 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 858 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 1151 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2008 | 808 | 0.010 |
Why?
|
| United States | 1 | 2015 | 7425 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2009 | 1471 | 0.010 |
Why?
|
| Animals | 2 | 2009 | 19650 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 4986 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2009 | 2903 | 0.010 |
Why?
|